-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company is focusing its efforts precisely to achieve its annual goals.
Category:
Time：2019-12-03
The fourth quarter is the golden season for the company’s production and operations, as well as the concluding quarter for achieving the company’s annual development goals. In response to the call to “fight hard in the fourth quarter and fully accomplish the year’s strategic objectives,” the entire company has launched a vigorous and enthusiastic campaign to make every possible effort during the fourth quarter, ensuring that we meet our annual production and operational targets.
The fourth quarter is the golden season for the company’s production and operations, as well as the concluding quarter for achieving the company’s annual development goals. In response to the call to “fight hard in the fourth quarter and fully accomplish the year’s strategic objectives,” the entire company has launched a vigorous and intense campaign to make every effort during the fourth quarter, ensuring that we meet our annual production and operational targets.
Since the beginning of this year, sales of the company’s ampoule products have remained robust. As of the end of September, sales of polypropylene ampoule vials for aqueous injections increased by 413% year-on-year. To boost production capacity, the ampoule product manufacturing workshop has been actively responding to market demand and operating at full capacity across the board. Production of the 5ml and 10ml sizes has been steadily ramped up, with daily output now exceeding 220,000 vials.
The sustained growth trajectory is inseparable from the company’s strong commitment to R&D and innovation. Relying on high-level innovation platforms such as the National Enterprise Technology Center, the company continuously strengthens both fundamental and cutting-edge basic research, focusing its innovative vision on areas like the development of major national innovative drugs. It is seizing opportunities to develop new and blockbuster products with significant market potential and high technological content.
In the first half of this year, the company obtained a total of 14 marketing approvals for generic drugs. Among them, the cardiovascular drug tirofiban hydrochloride sodium injection, which is clinically indicated for the treatment of acute coronary syndrome, is a therapeutic agent with significant potential for clinical promotion and represents the company’s flagship new product launched this year.
As we enter the fourth quarter, while R&D personnel are stepping up efforts to develop innovative drugs, they are also working with renewed vigor, concentrating human and material resources to accelerate research on the evaluation of generic drug quality and therapeutic equivalence. The number of injection applications submitted ranks among the highest in the industry.
Faced with the new market conditions, the operating company has adapted to the trend by promptly adjusting its strategy and stepping up efforts in the sales and performance evaluation of therapeutic products such as moxifloxacin hydrochloride sodium chloride injection, abidol hydrochloride capsules, and bromhexine hydrochloride glucose injection, as well as large-size soft-bag products. While maintaining its leading position in the intravenous solution market, the company is also expanding its market share for therapeutic products.
At this critical juncture of the fourth quarter sprint, in order to further boost the work enthusiasm of sales personnel and support the company’s achievement of its annual targets, the company’s trade union has issued the “Arrangements for Launching the Sales Competition among Operating Companies,” thereby rallying support and energy for the fourth-quarter sales competition. Su Xuejun, General Manager of the company, stated that the company will enter the fourth quarter with its best spirit, make every effort to achieve outstanding results, and ensure the successful completion of all annual goals and tasks, thus making new contributions to the company’s high-quality development and the growth of the Shijiazhuang pharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license